How To Optimize Your Safety Pharmacology Studies

Safety pharmacology studies are a cornerstone of drug development, assessing the risk of adverse physiological effects posed by new pharmaceutical products. As a critical component of most IND-enabling drug safety programs, these studies are essential for ensuring safety and regulatory compliance. Recognizing their importance, many Sponsors also integrate exploratory safety pharmacology studies during discovery and early development to guide pivotal project decisions.

In an insightful webinar presented by Dr. Michael R. Gralinski, the vital role of safety pharmacology studies in the drug approval process will be discussed, along with strategies to enhance cardiovascular, CNS, respiratory, and ion channel studies to prevent potentially catastrophic delays. Hosted by Altasciences and CorDynamics, the webinar will offer valuable guidance on optimizing study designs, overcoming challenges related to environment, species selection, instrumentation, and data analysis, and choosing the right CRO partner for your safety pharmacology studies.

About the Presenter
Dr. Michael R. Gralinski, Chief Executive Officer and Co-founder of CorDynamics, brings extensive expertise in pharmaceutical development, including product safety, toxicology, and safety pharmacology. A former President of the Safety Pharmacology Society, Dr. Gralinski holds a B.S. in Pharmacology and Toxicology from the University of Wisconsin-Madison and a Ph.D. in Pharmacology (Cardiovascular) from the University of Michigan. His leadership and experience ensure an engaging and informative exploration of this essential aspect of drug development.